Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Health Care, Inc. on January 18, 2024. The transaction is expected to close on February 1, 2024, subject to customary closing conditions. The assets includes laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG?s CLIA-certified laboratory in St.

George, Utah where the Precise Tumor Test is currently performed.